Congratulations to these CHS art students for winning ribbons at last weekend’s Red River Valley Fair art exhibit.

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood Journal , 2024; DOI: 10.1182/blood.2024025945 Cite This Page : ...

That's why spreading awareness and encouraging early detection is so important, and that is exactly what The Pink Ribbon campaign aims to do with our informative content, in conjunction with Breast ...

And last month we learned that Springsteen’s wife (and member of the E Street Band), Patti Scialfa, has been living for years with multiple myeloma since her 2018 diagnosis. Scialfa, 71 ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti has once again mounted a ...

The CARTITUDE-4 study found that cilta-cel reduced the risk of death by 45% compared to standard of care in patients with multiple myeloma. Treatment with the CAR T-cell therapy ciltacabtagene ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma last week, J&J has wasted little time hitting back with new data on its ...

How will the results of the CEPHEUS study be used to inform the treatment of patients with newly diagnosed multiple myeloma? Based on the CEPHEUS clinical trial, the transplant-ineligible or ...

“The findings provide mounting evidence that environmental exposures – and exposure to the World Trade Centre disaster in general – are risk factors for the initiation of multiple myeloma ...

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it affec ...